Tysabri and PML: Key Symptoms and Monitoring Timeline

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Assessment

If you or a loved one is on Tysabri, knowing the early signs of progressive multifocal leukoencephalopathy (PML) is critical. Symptoms like subtle weakness, vision changes, or confusion can appear weeks to months after exposure. This page draws on established medical surveillance protocols to help you recognize when to seek evaluation and what documentation supports accurate diagnosis.

Bridging General Awareness to Specific Litigation Criteria

The bridge concept thus connects general health awareness with the specific, quantifiable parameters of exposure that define legal and clinical outcomes. Tysabri (natalizumab) is a biologic therapy approved for the treatment of relapsing forms of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. This narrative reviews the clinical presentation and diagnosis of PML, the pharmacology of Tysabri, the mechanistic link between the drug and PML, and settlement-related considerations for affected patients.

Clinical Presentation and Diagnosis of PML

Progressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system caused by reactivation of the JC virus. Clinical presentation typically includes subacute onset of neurological deficits such as hemiparesis, visual field defects, ataxia, cognitive decline, and speech disturbances. Diagnosis relies on brain MRI showing multifocal, asymmetric white matter lesions without mass effect, and detection of JC virus DNA in cerebrospinal fluid by polymerase chain reaction. Brain biopsy may be required in equivocal cases. PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Pharmacology of Tysabri and Mechanism of PML Risk

Tysabri is a humanized monoclonal antibody that binds to alpha-4 integrin, blocking adhesion of leukocytes to vascular endothelium and reducing their migration into the central nervous system. This mechanism is therapeutic in multiple sclerosis and Crohn's disease but impairs immune surveillance in the brain. The drug's pharmacology includes a long half-life and sustained biological effect, which contributes to the risk of opportunistic infections. In clinical trials, PML occurred in three patients who received Tysabri: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves reduced immune surveillance in the central nervous system. By inhibiting lymphocyte trafficking into the brain, Tysabri prevents the normal immune response that controls JC virus replication. The virus, which is latent in most individuals, can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination. Three established risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.

Litigation and Settlement Considerations

The adequacy of warnings regarding Tysabri and PML is a central issue in litigation. The prescribing information includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning advises monitoring patients and withholding Tysabri immediately at the first sign or symptom suggestive of PML. Because of the risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, plaintiffs have argued that the risks were not adequately communicated to patients and that earlier detection could have reduced harm. Settlement-related considerations for affected patients include the timeline between exposure and documented harm. PML typically develops after prolonged Tysabri exposure, with risk increasing beyond two years of treatment. In clinical trials, the two multiple sclerosis patients developed PML after a median of 120 weeks (approximately 2.3 years) of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The Crohn's disease patient developed PML after eight doses, indicating that shorter exposure does not eliminate risk. Settlement criteria often consider the duration of Tysabri use, presence of anti-JCV antibodies, prior immunosuppressant use, and the severity of neurological impairment. Patients who develop PML may face lifelong disability or death, and settlements aim to compensate for medical expenses, lost income, and pain and suffering.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to reduced immune surveillance in the central nervous system.

What are the key risk factors for developing PML while on Tysabri?

Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when initiating and continuing therapy.

What settlement criteria are considered for Tysabri-related PML lawsuits?

Settlement criteria often include duration of Tysabri use, presence of anti-JCV antibodies, prior immunosuppressant use, and severity of neurological impairment. Compensation may cover medical expenses, lost income, and pain and suffering.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.